{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:49:21Z","timestamp":1781196561110,"version":"3.54.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T00:00:00Z","timestamp":1745020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T00:00:00Z","timestamp":1745020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100018731","name":"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018731","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s13318-025-00944-5","type":"journal-article","created":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T11:20:52Z","timestamp":1745061652000},"page":"265-272","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Phase I Study to Evaluate the Relative Bioavailability, Pharmacodynamics, and Safety of a Single Subcutaneous Injection of Recaticimab at Three Different Sites in Healthy Chinese Subjects"],"prefix":"10.1007","volume":"50","author":[{"given":"Ying","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanzhi","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renpeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0439-635X","authenticated-orcid":false,"given":"Kai","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,19]]},"reference":[{"issue":"8","key":"944_CR1","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1161\/CIR.0000000000001209","volume":"149","author":"SS Martin","year":"2024","unstructured":"Martin SS, Aday AW, Almarzooq ZI, et al. 2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation. 2024;149(8):e347\u2013913. https:\/\/doi.org\/10.1161\/CIR.0000000000001209.","journal-title":"Circulation"},{"issue":"24","key":"944_CR2","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","volume":"41","author":"J Bor\u00e9n","year":"2020","unstructured":"Bor\u00e9n J, Chapman MJ, Krauss RM, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020;41(24):2313\u201330. https:\/\/doi.org\/10.1093\/eurheartj\/ehz962.","journal-title":"Eur Heart J"},{"issue":"5","key":"944_CR3","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.mcna.2024.03.005","volume":"108","author":"J Wright","year":"2024","unstructured":"Wright J, Subramanian S. Therapy for hyperlipidemia. Med Clin North Am. 2024;108(5):881\u201394. https:\/\/doi.org\/10.1016\/j.mcna.2024.03.005.","journal-title":"Med Clin North Am"},{"issue":"14","key":"944_CR4","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","volume":"80","author":"DM Lloyd-Jones","year":"2022","unstructured":"Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;80(14):1366\u2013418. https:\/\/doi.org\/10.1016\/j.jacc.2022.07.006.","journal-title":"J Am Coll Cardiol"},{"key":"944_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108480","volume":"249","author":"S Hummelgaard","year":"2023","unstructured":"Hummelgaard S, Vilstrup JP, Gustafsen C, et al. Targeting PCSK9 to tackle cardiovascular disease. Pharmacol Ther. 2023;249: 108480. https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108480.","journal-title":"Pharmacol Ther"},{"issue":"3","key":"944_CR6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41569-018-0107-8","volume":"16","author":"MS Sabatine","year":"2019","unstructured":"Sabatine MS. PCSK9 inhibitors: clinical evidence and implementation. Nat Rev Cardiol. 2019;16(3):155\u201365. https:\/\/doi.org\/10.1038\/s41569-018-0107-8.","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"944_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12916-021-02208-w","volume":"20","author":"M Xu","year":"2022","unstructured":"Xu M, Zhu X, Wu J, et al. PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b\/2 study. BMC Med. 2022;20(1):13. https:\/\/doi.org\/10.1186\/s12916-021-02208-w.","journal-title":"BMC Med"},{"issue":"20","key":"944_CR8","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1016\/j.jacc.2024.07.035","volume":"84","author":"M Xu","year":"2024","unstructured":"Xu M, Wang Z, Zhang Y, et al. Recaticimab monotherapy for nonfamilial hypercholesterolemia and mixed hyperlipemia: the phase 3 REMAIN-1 randomized trial. J Am Coll Cardiol. 2024;84(20):2026\u201336. https:\/\/doi.org\/10.1016\/j.jacc.2024.07.035.","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"944_CR9","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1016\/j.jacc.2024.09.012","volume":"84","author":"Y Sun","year":"2024","unstructured":"Sun Y, Lv Q, Guo Y, et al. Recaticimab as add-on therapy to statins for nonfamilial hypercholesterolemia: the randomized, phase 3 REMAIN-2 trial. J Am Coll Cardiol. 2024;84(20):2037\u201347. https:\/\/doi.org\/10.1016\/j.jacc.2024.09.012.","journal-title":"J Am Coll Cardiol"},{"key":"944_CR10","unstructured":"US Department of Health and Human Services, US Food and Drug Administration, Center for Drug Evaluation and Research, et al. Bioavailability studies submitted in NDAs or INDs\u2014General considerations guidance for industry. 2022. https:\/\/www.fda.gov\/media\/121311\/download. Accessed 15 April 2022."}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-025-00944-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-025-00944-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-025-00944-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T14:09:31Z","timestamp":1747318171000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-025-00944-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,19]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["944"],"URL":"https:\/\/doi.org\/10.1007\/s13318-025-00944-5","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,19]]},"assertion":[{"value":"16 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was funded by Jiangsu Hengrui Pharmaceuticals Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Ying Wang, Yuhan Guo, Yang Fan, Ye Xu, Sheng Feng, and Kai Shen are employees of Jiangsu Hengrui Pharmaceuticals Co., Ltd. The other authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The data that support the findings of this study are available on request from the corresponding authors. The data are not publicly available owing to privacy or ethical restrictions.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"All procedures performed in this study were in accordance with the Declaration of Helsinki, the good clinical practice guidelines of the International Conference on Harmonization, and local laws and regulations. The study was approved by the Ethics Committees of the Second Affiliated Hospital of Anhui Medical University, Hefei, China (ethics approval number YW2022-044, date: March 21 2022).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written informed consent was obtained from all subjects prior to screening.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Wei Hu was the principal investigator and made substantial contributions to the study design. Renpeng Zhou and Qian Zhang performed the study and data acquisition. Ying Wang, Yuhan Guo, and Yang Fan were involved in data analysis and interpretation. Ying Wang drafted the paper, and Kai Shen, Wei Hu, Sheng Feng, Ye Xu, and Yuanzhi Cheng reviewed and revised the manuscript critically for intellectual content. All authors read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}